EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieKlinische Studie (Phase II)Open Access · CC BY-NC-ND 4.0

Efficacy and Safety of Switching to Daily Bictegravir Plus Lenacapavir From a Complex HIV Treatment Regimen: A Randomized, Open-Label, Multicenter Phase 2 Study (ARTISTRY-1)

Karam Mounzer iD, Jihad Slim iD, Moti Ramgopal, Malcolm Hedgcock, Mark Bloch, Jorge Santana iD, Ines Mendes iD, Ying Guo, Priyanka Arora iD, Jairo M Montezuma-Rusca, Peter Sklar iD, Jared M Baeten und 1 weitere

Clinical Infectious Diseases · 30.04.2025 · 80 (4) · 881-888

DOI: 10.1093/cid/ciae522 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Infectious Diseases, online erschienen am 26.11.2024. Verfasst von Karam Mounzer und 12 weiteren Autor:innen. Beteiligte Einrichtung: The Jonathon Lax Immune Disorders Treatment Center, Philadelphia FIGHT, Philadelphia, Pennsylvania, USA. Hauptthemen laut MEDLINE: HIV Infections, Anti-HIV Agents, Heterocyclic Compounds, 4 or More Rings, Quinolones. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Gilead Sciences..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Complex antiretroviral therapy (ART) regimens, such as those requiring multiple tablets, several doses per day, or both, can negatively affect quality of life and treatment adherence among people with human immunodeficiency virus (HIV).

Methods

ARTISTRY-1 is a phase 2/3, operationally seamless, randomized, open-label, multicenter, active-controlled study (GS-US-621-6289; NCT05502341). Phase 2 of the study enrolled adults with plasma HIV-1 RNA <50 copies/mL receiving a complex ART regimen for ≥6 months. Efficacy and safety outcomes were evaluated after a switch to bictegravir (BIC) (75-mg) + lenacapavir (LEN) (25- or 50-mg) regimens, compared with continuing on a complex ART regimen through 24 weeks.

Results

Overall, 128 participants were assigned randomly to begin BIC 75 mg + LEN 25 mg (n = 51) or BIC 75 mg + LEN 50 mg (n = 52) or continue on their complex ART regimen (n = 25). At week 24, HIV-1 RNA was ≥50 copies/mL in 0 of 51, 1 of 52 (1.9%), and 0 of 25 participants in the 3 groups, respectively. CD4 cell counts and percentages remained stable through week 24; the median change from baseline in CD4 cell count (interquartile range) was 18 (−39 to 70), −16 (−80 to 93), and 42 (−36 to 90) cells/µL, respectively. There were no study discontinuations due to a serious adverse event through week 24. Both BIC + LEN dosing regimens were well tolerated, with similar safety profiles observed between groups.

Conclusions

These data support the continued evaluation of the combination of BIC and LEN to optimize treatment in people with HIV and virologic suppression who are receiving complex ART regimens.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV InfectionsAnti-HIV AgentsHeterocyclic Compounds, 4 or More RingsQuinolonesHumansMaleAdultFemaleMiddle AgedHIV-1Treatment OutcomeViral LoadDrug Therapy, CombinationCD4 Lymphocyte CountRNA, ViralPiperazinesPyridonesIndazolesAcetamidesHeterocyclic Compounds, 3-RingAmides

Stichwörter der Autor:innen

antiretroviral therapybictegravirefficacylenacapavirsafety

Substanzen

Anti-HIV AgentsbictegravirHeterocyclic Compounds, 4 or More RingsQuinolonesRNA, VirallenacapavirPiperazinesPyridonesIndazolesAcetamides

Autor:innen und Institutionen

  • The Jonathon Lax Immune Disorders Treatment Center, Philadelphia FIGHT, Philadelphia, Pennsylvania, USA.
  • New York Medical College, Valhalla, New York, USA.
  • Midway Immunology and Research Center, Fort Pierce, Florida, USA.
  • Spectrum Health, Vancouver, British Columbia, Canada.
  • Holdsworth House Medical Practice, Darlinghurst, New South Wales, Australia.
  • School of Medicine, University of Puerto Rico, San Juan, Puerto Rico.

ORCID-Profile: Karam Mounzer, Jihad Slim, Jorge Santana, Ines Mendes, Priyanka Arora, Peter Sklar, Sorana Segal-Maurer

Förderung

  • Gilead Sciences.

Zitieren

APA

Mounzer, K., Slim, J., Ramgopal, M., Hedgcock, M., Bloch, M., Santana, J., Mendes, I., Guo, Y., Arora, P., Montezuma-Rusca, J. M., Sklar, P., Baeten, J. M., & Segal-Maurer, S. (2025). Efficacy and Safety of Switching to Daily Bictegravir Plus Lenacapavir From a Complex HIV Treatment Regimen: A Randomized, Open-Label, Multicenter Phase 2 Study (ARTISTRY-1). Clinical Infectious Diseases, 80(4), 881-888. https://doi.org/10.1093/cid/ciae522

Vancouver

Mounzer K, Slim J, Ramgopal M, Hedgcock M, Bloch M, Santana J, et al. Efficacy and Safety of Switching to Daily Bictegravir Plus Lenacapavir From a Complex HIV Treatment Regimen: A Randomized, Open-Label, Multicenter Phase 2 Study (ARTISTRY-1). Clinical Infectious Diseases. 2025;80(4):881-888. doi:10.1093/cid/ciae522

BibTeX
@article{Mounzer2025,
  author = {Mounzer, Karam and Slim, Jihad and Ramgopal, Moti and Hedgcock, Malcolm and Bloch, Mark and Santana, Jorge and Mendes, Ines and Guo, Ying and Arora, Priyanka and Montezuma-Rusca, Jairo M and Sklar, Peter and Baeten, Jared M and Segal-Maurer, Sorana},
  title = {Efficacy and Safety of Switching to Daily Bictegravir Plus Lenacapavir From a Complex HIV Treatment Regimen: A Randomized, Open-Label, Multicenter Phase 2 Study (ARTISTRY-1)},
  journal = {Clinical Infectious Diseases},
  year = {2025},
  volume = {80},
  number = {4},
  pages = {881--888},
  doi = {10.1093/cid/ciae522}
}
Kostenlos starten →